Paraneoplastic cerebellar degeneration

Paraneoplastic cerebellar degeneration
Synonyms	N/A
Pronounce	N/A
Specialty	N/A
Symptoms	Ataxia, dysarthria, nystagmus
Complications	Progressive neurological decline
Onset	Subacute
Duration	Chronic
Types	N/A
Causes	Autoimmune response to cancer
Risks	Underlying malignancy
Diagnosis	Clinical evaluation, MRI, serological tests
Differential diagnosis	N/A
Prevention	N/A
Treatment	Immunotherapy, treatment of underlying cancer
Medication	N/A
Prognosis	Variable, often poor
Frequency	N/A
Deaths	N/A

Paraneoplastic cerebellar degeneration (PCD) is a rare neurological disorder associated with cancer, characterized by the rapid onset of cerebellar dysfunction. It is part of a group of disorders known as paraneoplastic syndromes, which occur when the immune system's response to a neoplasm (tumor) mistakenly attacks the nervous system.

Pathophysiology

PCD is believed to be caused by an autoimmune response triggered by the presence of a neoplasm. The immune system produces antibodies that target antigens expressed by both the tumor and the cerebellum. These antibodies can cross the blood-brain barrier and lead to inflammation and degeneration of cerebellar neurons. Common antibodies associated with PCD include anti-Yo, anti-Hu, and anti-Tr antibodies.

Clinical Presentation

Patients with PCD typically present with subacute onset of cerebellar symptoms. These may include:

• Ataxia: A lack of voluntary coordination of muscle movements, often manifesting as gait instability.
• Dysarthria: Difficulty in articulating words due to lack of coordination of the muscles used in speech.
• Nystagmus: Involuntary, rapid, and repetitive movement of the eyes.

Other symptoms may include dysphagia (difficulty swallowing) and vertigo.

Diagnosis

The diagnosis of PCD is primarily clinical, supported by laboratory and imaging studies. Key steps in the diagnostic process include:

• Clinical Evaluation: Detailed neurological examination to assess cerebellar function.
• Magnetic Resonance Imaging (MRI): May show cerebellar atrophy or other changes.
• Serological Tests: Detection of paraneoplastic antibodies such as anti-Yo, anti-Hu, or anti-Tr.
• Cancer Screening: Identification of an underlying malignancy, often breast cancer, ovarian cancer, or small cell lung cancer.

Treatment

The primary approach to managing PCD involves treating the underlying cancer and modulating the immune response. Treatment options include:

• Immunotherapy: Use of corticosteroids, intravenous immunoglobulin (IVIG), or plasmapheresis to reduce the autoimmune attack on the cerebellum.
• Cancer Treatment: Surgical resection, chemotherapy, or radiation therapy to treat the underlying malignancy.

Prognosis

The prognosis of PCD is variable and often depends on the type and stage of the underlying cancer, as well as the patient's response to treatment. In many cases, the neurological deficits are progressive and may not fully resolve even with treatment of the cancer.

See Also

• Paraneoplastic syndrome
• Cerebellar ataxia
• Autoimmune disease

External Links

• [Link to relevant medical resources]